2020
DOI: 10.1016/j.vaccine.2019.12.040
|View full text |Cite
|
Sign up to set email alerts
|

Vaccine efficacy of recombinant BmVDAC on Rhipicephalus microplus fed on Babesia bigemina-infected and uninfected cattle

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

0
4
0

Year Published

2021
2021
2024
2024

Publication Types

Select...
6
2

Relationship

1
7

Authors

Journals

citations
Cited by 11 publications
(4 citation statements)
references
References 51 publications
0
4
0
Order By: Relevance
“…Among cattle immunized with recombinant BmVDAC, the efficacy against R. microplus was found to be 82%. Interestingly, when ticks were infected with B. bigemina, the reported efficacy of recombinant BmVDAC decreased to 34% (ORTEGA-SANCHEZ et al, 2020).…”
Section: Potential Antigens For the Control Of R Microplusmentioning
confidence: 99%
“…Among cattle immunized with recombinant BmVDAC, the efficacy against R. microplus was found to be 82%. Interestingly, when ticks were infected with B. bigemina, the reported efficacy of recombinant BmVDAC decreased to 34% (ORTEGA-SANCHEZ et al, 2020).…”
Section: Potential Antigens For the Control Of R Microplusmentioning
confidence: 99%
“…Additionally, vaccines can complement other ixodid control tactics with the aim of mitigating the development of resistance to acaricides [ 250 ] Vaccines can be designed to deploy multiple antigens, enabling protection for a wide range of host species against multiple ixodid species [ 251 ]. As an example of current efforts to develop anti-ixodid vaccines, candidate vaccines are being investigated with the goal of providing prophylactic protection of cattle from R. microplus [ 252 ], while recent efforts using recombinant antitick vaccines afforded nearly 82% efficacy against tick infestation [ 253 ]. Additional vaccine development opportunities exist, with a current focus on improving identification and characterization of ixodid antigens that can then be generated in the laboratory [ 254 ].…”
Section: Vaccinesmentioning
confidence: 99%
“…Putatively concealed 7 Willadsen et al, 1996;McKenna et al, 1998;Andreotti et al, 2002;Patarroyo et al, 2002;Hajdusek et al, 2010;Almazán et al, 2012;Parizi et al, 2012;Seixas et al, 2012;Díaz-Martín et al, 2013;Merino et al, 2013;Ali et al, 2014;Guerrero et al, 2014;Radulović et al, 2014;Tirloni et al, 2014;Richards et al, 2015;Rodríguez-Mallon et al, 2015;Tirloni et al, 2015;Kumar et al, 2017;Maruyama et al, 2017;Tirloni et al, 2017;Csordas et al, 2018;Kim et al, 2020;Ortega-Sánchez et al, 2020 Acknowledgements BFL received a scholarship from CAPES, Brasil.…”
Section: Categoriesmentioning
confidence: 99%